Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
– Trial Will Compare NXL103 With Leading Oral Agent Linezolid for the
Treatment of Multi-Resistant Staphylococcus Aureus (MRSA) Infections
Novexel, a speciality pharmaceutical company focused on the discovery and
development of novel antibiotics designed to overcome the significant global
problem of microbial resistance, announces today that its most advanced oral
antibacterial NXL103 (flopristin/linopristin), has started a Phase II
clinical trial in adults with acute bacterial skin and skin structure
infections (ABSSSI). The trial is designed to assess the safety and efficacy
of NXL103 in comparison to oral linezolid (Zyvox, Pfizer NYSE:PFE).
The comparative Phase II trial with NXL103 is a prospective, multicenter,
investigator-blinded, two-arm, parallel group study carried out in adults,
either in hospital or as outpatients, with ABSSSI. Patients will be
randomized to receive either NXL103 (500 mg twice a day) or linezolid (600mg
twice a day), with 120 patients receiving NXL103 and 60 receiving linezolid.
The treatment period in both study arms will be between 10 and 14 days.
The primary endpoint of the study is the clinical outcome in the
clinically evaluable population at the Test of Cure (TOC) visit (7 days
post-therapy). Secondary end points of the study include microbiological
response at the TOC visit as well as evaluating the tolerability and safety
This comparative Phase II study is expected to recruit a total of 180
patients from approximately 20 sites in the
study is expected to be completed in 2010 and is a critical part of Novexel’s
clinical development plan for NXL103 which is focused on its potential to be
used in hospitals and out-patients as an oral agent for the treatment of
infections caused by Gram-positive organisms, including MRSA. Currently,
physicians have a limited choice of anti-MRSA antibacterials when they wish
to switch from intravenous (IV) to oral treatment, a key step prior to a
patient being able to be discharged from the hospital.
NXL103, as a member of the Streptogramin class of antibiotics, has a
unique mode of action, with its two components acting synergistically to
inhibit the bacterial ribosome. Its spectrum of activity indicates its
potential to be effective in the treatment of ABSSSI, including those caused
by resistant pathogens such as MRSA.
In late 2008, Novexel announced positive results from a Phase II clinical
trial evaluating NXL103 in the treatment of community acquired pneumonia
with NXL103 is another important step in the growth of the company. There is
a clear need for products that can be used to manage the release of patients
from hospital by allowing them to be switched from intravenous to oral
Notes to Editors
About NXL 103
NXL103 is a novel oral antibiotic made up of two streptogramin
antibiotics, linopristin and flopristin, which act synergistically to inhibit
the bacterial ribosome. NXL103 is a bactericidal antibiotic and in vivo
studies have shown that this novel antibiotic is not affected by either
beta-lactam or common macrolide resistance mechanisms. Positive results for a
Phase II trial with NXL103 in the treatment of community acquired pneumonia
(CAP) were reported towards the end of 2008. NXL103 is currently in a Phase
II trial for the treatment of ABSSSI.
ABSSSI (Acute Bacterial Skin and Skin Structure Infections) are
infections that involve deeper tissue or require surgical intervention (e.g.
cellulitis, major cutaneous abscesses, and infected wounds) or are associated
with a significant underlying disease that complicates response to therapy. A
variety of pathogens may be identified in ABSSSI but the two most common
Gram-positive pathogens are Staphylococcus aureus and Streptococcus pyogenes.
The significant increase in the incidence of MRSA in community as well as
hospital acquired infections has resulted in a need for empirical therapy of
ABSSSI that is effective against MRSA.
Novexel is a speciality pharmaceutical company focused on the discovery
and development of novel antibiotics designed to overcome the significant
global problem of microbial resistance. The ever increasing resistance to
marketed antibiotics has led to a clear need for novel drugs that are active
against multi-drug resistant bacteria. Novexel’s products are targeting the
global hospital antibiotic market, which was worth an estimated
In addition to NXL103, Novexel is currently conducting two Phase II
studies with NXL104 in combination with the cephalosporin antibiotic
ceftazidime (CAZ/104) for serious Gram-negative infections. Patient
recruitment in those studies (a) with complicated intra-abdominal infections
(cIAIs) and (b) with complicated urinary tract infections (cUTIs) is nearing
completion with the results expected in the first half of 2010.
A recent technical report from the European Centre for Disease Prevention
and Control (ECDC) and the European Medicines Agency (EMEA) entitled “The
bacterial challenge: time to react,”(2) voiced the need to narrow the gap
between multi-resistant bacteria in the EU and the development of new
antibacterial agents. In particular the report highlighted the growing
problem of infections caused by multi-resistant Gram negative bacteria
including Pseudomonas aeruginosa. These are the types of infections that
Novexel is targeting with CAZ/104.
Novexel has three further programmes in preclinical development, NXL105,
a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal
agent, and NXL104 in combination with ceftaroline. This latter product is
being developed by Novexel’s partner, Forest Laboratories (NYSE: FRX), solely
for North American markets.
Novexel was created in
sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel
has a team of 54 employees with significant experience in anti-infective
research and development, who are located in
(1) Source: IMS Health, MIDAS, 2006-2008
(2) “The bacterial challenge: time to react, A call to narrow the gap
between multidrug-resistant bacteria in the EU and the development of new
antibacterial agents”, ECDC/EMEA Joint Technical Report, September, 2009
For further information please contact: Novexel Gordon Waldron, CFO firstname.lastname@example.org Citigate Dewe Rogerson Amber Bielecka/David Dible/Nina Enegren Tel.: +44(0)207-638-95-71 email@example.com